The research presented in the article, "Communications of Drug Affordability Between Physicians and Elderly Patients," was designed to identify patient characteristics that were related to physician-patient communications on medication affordability. 1 In this article, Xu and Irons present a portion of the results of a telephone survey of 5,000 persons living in West Texas who were identified as being ≥65 years old. The information collected included cognitive function, the use of health and pharmaceutical services, satisfaction with access and quality, insurance coverage, demographics, and other financial and health status characteristics. The authors focused their discussion on the association between several of these characteristics and the respondents' answers (yes or no) to the question "In the past 12 months, has your physician ever asked whether you can afford a drug?" Data collected yielded 2,360 usable sets of responses. Eleven percent of those responding remembered their physician asking whether they were able to afford their prescribed medications.
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Xu and Irons suggest that, when prescribers fail to communicate with patients, pharmacists are in a distinctive position that allows them to (1) offer generic products, (2) communicate cost and choice of therapy information, (3) be aware of cost issues, (4) notify the prescriber of the availability of products that have similar effect and lower cost, when cost/affordability impacts adherence, and (5) serve as a "double-check guard" of cost/affordability to decrease the financial impact of medications when prescribers fail to communicate with patients regarding these issues. Although this is an important service that pharmacists deliver, it is only a beginning. Today, many pharmacists do much more than act as the double-check guard. There are many new and emerging roles for pharmacists. However, for efficient and effective patient care, communication and collaboration between pharmacists and prescribers must progress and, in many cases, have progressed beyond the level suggested by Xu and Irons.
In 2001, McDonough and Doucette discussed the need to improve patient care by coordinating activities among providers of care, the use of collaborative practice agreements, and models for stages of pharmacist-physician collaborative working relationships. 2 The stages presented in this model range from Stage 0, Professional Awareness, to Stage 4, Commitment to the Collaborative Working Relationship. Pharmacists bring a unique set of skills to this relationship; they have the knowledge to improve drug therapy and the ability to help the patient improve self-care. When pharmacists work in collaborative relationships, the benefit to the patient is maximized. The interactions presented by Xu 
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v When pharmacists work in collaborative relationships, the benefit to the patient is maximized.
w providers and interactions remain discrete and of short duration. At this stage, little thought has been given to forming a relationship. In Stage 1 of the McDonough and Doucette model, Professional Recognition, a 1-way effort to develop a relationship begins, usually with a pharmacist making an effort to increase the level of patient information provided and to increase contact with a prescriber. The increased contact may allow the pharmacist to provide information on new services that may be beneficial to the prescriber's patients. Contact regarding the development and formation of a disease state management screening and monitoring program would be an example of this stage of a relationship.
Stage 2, Exploration and Trial, is characterized by the beginning of a collaborative arrangement, such as a disease state management screening and monitoring program, during which both practitioners test the relationship. If expectations are met, the relationship should continue to grow as additional expectations are explored and boundaries and goals are established. Stage 3, Professional Relationship Expansion, and Stage 4, Commitment to Collaborative Working Relationship, are distinguished by an expansion in communication, identification and resolution of conflict, and increased interdependence to provide quality patient care. They are exemplified by an evolving, ongoing relationship in which pharmacists provide patient care with feedback to physicians that progresses to a formal collaborative practice agreement.
For example, we work with the staff at Valley Mountain Regional Center (VMRC), a center for individuals with developmental disabilities, to deliver pharmaceutical care to VMRC consumers. Over time, this working relationship went through each of the stages summarized by McDonough and Doucette. Stage 0 consisted of short, directed questions from 1 physician with answers on medications provided by 1 or 2 of the university pharmacists. There was no ongoing follow-up and no plan for a long-term relationship. Stages 1 and 2 were characterized by planning and outreach, with all parties working together to determine how services and compensation for services could be delivered. This relationship has been formalized and could now be considered a collaborative practice agreement. It is currently in Stage 4 and continues to grow and strengthen.
One activity that pharmacists participate in is the annual wellness reviews. A component of these reviews is the gathering of a medication history for each of VMRC's consumers. The medication history information is forwarded to a university consultant pharmacist for review and confirmation. From this information, a database is developed of all consumers taking psychotropic medications. Drug information is validated and charts are reviewed for pertinent information such as monitoring laboratory data, diagnosis, dose, adverse events, and outcomes. When problems or concerns are identified, the pharmacist initiates a team meeting including a physi-cian, nurse advocate, case worker, and other specialists as determined by patient needs. During this meeting, the patient issues are discussed among the team members. The pharmacist coordinates consumer care considerations that arise from this meeting. As this relationship progressed, the role of the pharmacists advanced from that of drug information source alone to an integrated member of the healthcare team. This role continues to evolve as additional needs are identified, and the service emphases are redefined based on regional center consumer needs. 3,4
A variety of factors impact collaborative relationships and practice agreements, and not all pharmacists and providers will be willing and able to participate in this type of working arrangement. However, for those who are able and for the patients for whom they provide care, these arrangements may hold the promise of improved outcomes. Most communication with prescribers is an opportunity to begin a relationship, allowing pharmacists to do much more than serve as double-check guards of cost and affordability. Members of our profession have the education, postgraduate training, practice experience, and expertise to develop collaborative working relationships and practice arrangements that will allow us to practice at a higher level. The need for the double-check guard still exists, but as alternative practice patterns and collaborative practices emerge, the days of serving only in that role may be numbered.
